Australia markets closed

Swedish Orphan Biovitrum AB (publ) (SOBI.ST)

Stockholm - Stockholm Real-time price. Currency in SEK
Add to watchlist
235.70-0.30 (-0.13%)
At close: 05:29PM CET
Full screen
Loading interactive chart…
  • PR Newswire

    Changes to Sobi's management

    Anton (Tony) Hoos, M.D., Ph.D., MBA will become Head of R&D and Medical Affairs and Chief Medical Officer and replace Anders Ullman, M.D., Ph.D. who will retire. Dr Hoos brings more than three decades of experience from the global pharmaceutical industry, including positions at Amgen, GSK and Aventis and most recently as a member of the board of Patient Focused Medicine Development, a non-profit organisation dedicated to bringing the voice of patients into the development of medicines. Similar t

  • PR Newswire

    Invitation: Sobi's Q4 and FY 2022 report

    Sobi plans to publish its report for the fourth quarter and full year of 2022 on 8 February 2023 at 08:00 CET.

  • PR Newswire

    NEJM publishes data demonstrating clinically meaningful prevention of bleeds and superior bleed protection for efanesoctocog alfa

    Pivotal study data published in The New England Journal of Medicine (NEJM) continues to highlight the efficacy, safety, and pharmacokinetic profile of efanesoctocog alfa (formerly BIVV001), a potential new medicine for haemophilia A. These data demonstrate the clinical benefits of normal to near-normal factor activity levels (>40%) for the majority of the week achieved by once weekly efanesoctocog alfa dosing. Efanesoctocog alfa is currently under priority regulatory review in the US with a targ